Personalized medicine is a rapidly evolving health-care industry, in which an individual’s genetic profile is used to customize health management. Explosive advances in next-generation sequencing (NGS) and computational analyses have enabled the evaluation for prevention and early detection of cancers. With years of research and development experience in the field of NGS, Creative Biolabs has established an advanced SuPrecision™ platform to offer an accurate and high-throughput sequencing service to support cancer diagnosis and precision medicine.

Monoclonal antibodies are the most important type of biotechnological products after vaccines and recombinant proteins. They are the strategic commanding heights of biotechnology and biomedicine industries in the 21st century. After 35 years of development, monoclonal antibody technology has gone through four stages: murine, chimeric, humanized, and fully human monoclonal antibodies. In response to the COVID-19 outbreak, Creative Biolabs can provide the service of immunizing humanized antibody mice with SARS-CoV-2 surface protein to screen for therapeutic human monoclonal antibodies.

VLPs are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but lack the viral genome, and may produce safer and cheaper vaccine candidates. If the specific native viral proteins with immunosuppressive function are excluded from VLPs, the efficacy of these particles can be significantly enhanced. Compared with single protein or peptide, VLPs present more similar conformational epitopes to the original virus. Therefore, antibody reactivity or immune system response is expected to be significantly improved. Due to their highly repetitive surfaces, VLPs are able to induce strong B cell responses without adjuvants by effectively crosslinking specific receptors on B cells. Studies have shown that VLP vaccines can stimulate humoral and cellular immune responses, thus providing effective antiviral protection.

Vaccine research and development has become very urgent with the emergence of new diseases, increased burden of infectious disease, and growing concern regarding vaccine safety. Creative Biolabs has more than a decade of experience and deep expertise in vaccine discovery and development, and we are committed to supporting the vaccine research and development industry with efficient services and cutting-edge technology.

https://sars-cov-2.creative-biolabs.com/vaccine-discovery-services-for-sars-cov2.htm

The episode is a brief introduction to IVD antibody development.

Find more information and services at: https://www.creative-biolabs.com/drug-discovery/diagnostics/

live biotherapeutics drug discovery services, including strain identification and validation, analytical development and qualification, GMP manufacturing, cell bank creation and storage, fermentation, lyophilization, etc. available at https://live-biotherapeutic.creative-biolabs.com/